What Ingredient Houses Are Selling Is Process, Not Efficacy

What is the signal?

in-cosmetics Asia 2026 ran from 3 to 5 November at BITEC in Bangkok. Clariant unveiled three new ingredients at the show, and the sun care one is Eclipsogen CAP Duo Z. According to the company, it combines three organic UV filters (DHHB, EHT and BEMT) with zinc oxide in a single ready-to-use dispersion, in a cold-processable system. Clariant says it targets broad-spectrum SPF with uniform film forming and little white cast, and presents it as a way to simplify the formulation of high-protection sunscreen. The wider Eclipsogen CAP series uses the company's NanoCon encapsulation, which Clariant says safeguards UV filters and improves their dispersion.

BASF ran its booth at the same show under the theme "Beyond Beauty: Future Unlocked", arranging its launches around four pillars: Transformative Sensory, Invisible Protection, Intelligent Cleansing and Science-Driven Ingredients. Its new active is Lincare, derived from flaxseed hull oligosaccharides and aimed at skin recovery after laser procedures. The clinical results the company published are that a formulation containing 1% Lincare helped the skin barrier recover 21% faster than placebo, approximately 1.2 days earlier, and delivered up to 16% greater skin density after 56 days. On the sun protection side it showed Tinosorb A2B, its latest UV filter (INCI name Tris-Biphenyl Triazine), in sun care concepts, alongside an SPF 50 / PA++++ tone-up sun lotion concept and a 3 November seminar on post-procedure sun care.

Dow released four functional ingredients at once. DOWSIL EL-9400 Hybrid Elastomer Blend delivers a mattifying, soft-focus effect, and the company reports 97% bio-based carbon in a readily biodegradable carrier. DOWSIL 8190 Oil Gellant turns silicone and organic oil phases into soft or firm gels, with suggested uses in lip gloss, eyeliner, foundation and hair care. EcoSmooth Universal Fluid 2000 and 3000 are readily biodegradable emollients, one covering a slippery, non-tacky feel and the other conditioning and lubricity. Between them the four items span skin care, sun care, colour and hair.

Place the three companies' launches side by side and a shared pattern appears. The explanation that comes first is not a new efficacy claim but a reduction in formulation and process burden. A ready-to-use dispersion, a system that runs cold, a gellant that builds a phase, readily biodegradable emollients: these are all proposals about the conditions of making, not about what the finished product does. On top of that sit an active aimed at post-procedure skin and high-protection, tone-up sun care concepts. What ingredient houses are currently selling to brands is not a new claim but a less demanding formula and process.

A note on how far this reads. Everything above is material published by the ingredient suppliers themselves, not third-party comparative testing. Figures such as Lincare's 21% and 16% are clinical results at the raw-material level, and they do not mean that a finished product containing that ingredient produces the same outcome. Trade show launches also show the direction suppliers want to sell in, not a measurement of Asian market demand. Which UV filters may be used, and up to what limits, differs by market, so the judgement items below should be read as development conditions that apply after ingredient eligibility has been confirmed market by market from primary sources.

1. A sun care decision starts with the filter system, not the filter list

Until now the line written in a sun care brief was usually the target protection figure plus something like "organic and inorganic hybrid". What came after - how many filters of which type, dispersed in what order - was settled at the formulation stage. The dispersion Clariant launched reverses that order. Because three organic filters and zinc oxide are already bound into one unit, the planning-stage question rises earlier: not "which filters" but "do we combine filters ourselves or take a finished system".

The advantage of taking a finished dispersion is reproducibility. What determines the protection figure in a sunscreen is not only the choice of filters but the uniformity of the film formed on skin, and that uniformity hangs largely on the state of dispersion. Using a raw material where the supplier has completed the dispersion reduces the burden of re-matching dispersion conditions each run, and variables such as white cast or patchy film start inside a range the supplier has already pinned down. For a brand starting with small volumes, it is a choice that cuts the number of trials.

In exchange you give up three things. First, freedom of combination. If the filter set is bound together, you cannot drop a single ingredient when one of them is restricted in a given market; the whole system has to change. Second, cost structure. When the core raw material is one supplier's finished product, there is less room to move unit cost with alternative quotations. Third, documentation. Even if you add a single dispersion, the ingredient list has to be written out as the individual substances inside it, so the composition and content information of the system needs to be secured from the supplier in advance.

So the first thing to check when evaluating a dispersion is not the performance data but the list of target markets. The same filter may differ by market in whether it is permitted and at what use limit, and sunscreen products enter different review or notification procedures country by country. This article gives no figures for specific ingredient limits, because the supplier material does not contain them. What belongs in the brief is whether this system can be used as-is in every market you intend to sell in, and who confirmed that from which document.

One addition: choosing a dispersion does not make the protection figure a property of that ingredient. Emulsification structure, film formers, application amount and spreadability all affect the film, so figures from the supplier's concept formula cannot be transferred into your own product. It is safer to state in the brief that the protection figure is an item to be tested and fixed on the completed formulation.

• Whether you decided at the planning stage to combine filters individually or take a finished dispersion
• Whether composition and content data for the substances inside the dispersion were obtained from the supplier
• Whether that filter set was confirmed usable in every intended market, market by market
• Whether the brief states that the protection figure will be tested and fixed on the completed formulation

2. Cold processing changes testing scope before it changes cost

The condition Clariant attached to its dispersion is that it is cold-processable. That is usually presented as energy and time saved. It is true that removing heating and cooling steps shortens batch time and lowers equipment load. In a brief, however, the heavier item is not cost but testing scope.

Change the process temperature and the way the emulsion forms changes with it, which means stability data has to be built again. Separation under accelerated and long-term conditions, viscosity change in storage, shifts in colour and fragrance, and whether the film stays even in use are all items for re-confirmation. Having data for a texture previously made by hot emulsification does not let you carry it over to a cold-processed version. The same ingredient list should be treated as a different product.

The second item is equipment reproducibility. Cold processing removes the stage where materials are melted and mixed by heat, and in exchange it is often more sensitive to mixing speed, shear and order of addition. If a formula that performed well on a small laboratory mixer does not build the same film on production equipment, the problem is scale-up rather than the formula. When evaluating a new raw material it is safer to obtain the supplier's recommended process conditions and first confirm that the actual production line can reproduce them.

The third is filling. A texture made by cold processing may sit in a different fill temperature and viscosity band, which moves nozzle specification, fill speed and compatibility with the container material along with it. Sunscreens in particular are often high in viscosity, which makes losses at filling more likely. If you are changing the process route, it is better not to defer container selection until after the formula is locked.

In short, cold processing is not a way to make something cheaply; it is a decision that sets the scope of what has to be tested again. How the stability testing period is scheduled in the first run is decided here.

• Whether the supplier's recommended process conditions (temperature, mixing, order of addition) were obtained in writing
• Whether the schedule allows stability data for the cold-processed version to be built from scratch
• Whether it was confirmed first that laboratory conditions can be reproduced on production equipment
• Whether container and nozzle specifications were reviewed against the fill temperature and viscosity band

3. "Post-procedure skin" is a raw-material clinical, not a product claim

The other axis that stands out at this show is post-procedure skin. BASF's Lincare is an active aimed at recovery after laser procedures, and the same company held a seminar on post-procedure sun care on 3 November. It is a signal that in markets where skin procedures have become routine, ingredient suppliers are productising the use occasion of "what you apply afterwards" first.

For a brand that use occasion is attractive. The moment of use is clear, there is a recommendation route, and the repurchase cycle attaches to the procedure cycle. But the layer of evidence changes the moment that attraction is moved into product copy. Lincare's 21% and 16% are clinical results the company obtained with a formulation containing 1% of the ingredient. The fact that your product contains it does not let you state the same figures, and product-level labelling and advertising is an item to be substantiated on the product itself. Supplier material is grounds for choosing an ingredient, not grounds for a product claim.

Brought down to development conditions, something has to be settled on the formulation side first. If the use occasion is post-procedure skin, everything with irritation potential has to be reviewed again: whether to include fragrance and at what level, how to build the preservative system, and whether viscosity and spreadability allow a thin application without drag. The direction to take first is deciding what to remove rather than what more to add.

Packaging is settled alongside. Assuming post-procedure use, a dispensing route where fingers do not touch the contents, a structure that delivers a small dose accurately, and a review of single-use portions follow naturally. Small single-use formats have hygiene advantages but raise the number of components and the filling cost, so they have to be looked at together with the volume plan.

Finally, write down the distribution route in advance. Post-procedure products face different requirements in general consumer channels and in professional recommendation channels. Pack size, the depth of explanatory material and the way samples are provided all differ, and the item mix of the first run changes accordingly. Leave that line blank and you end up fitting one product to both routes and satisfying neither.

• Whether the principle of not transferring raw-material clinical figures into product copy is written down
• Whether items to remove, such as fragrance and the preservative system, were decided before items to add
• Whether low-contact dispensing and single-use formats were reviewed together with the volume plan
• Whether packaging and materials will be set to general-channel or professional-channel requirements

4. Changing a sensory ingredient adds documentation and sensory testing together

The four items Dow launched are not efficacy actives but raw materials that carry sensory feel and structure: an elastomer blend that creates a matte finish, a gellant that sets an oil phase into a gel, and two non-tacky emollients. The company reports 97% bio-based carbon for the elastomer blend, and describes the two emollients and the carrier as readily biodegradable.

A growing supply of such materials creates two jobs. One is documentation. To mention bio-based content or biodegradability on the product side, you need material that states which test method produced the value and whether it applies at raw-material or finished-product level. The fact that one ingredient biodegrades does not become a property of the whole product containing it. It is worth checking whether that distinction is made in the supplier material you receive.

The other is sensory evaluation. Swap an existing silicone-based material for another class and spreadability, slip, finish and residue all change with it. In sun care and colour in particular that change connects directly to white cast, adhesion and wear. Even a swap that changes a single line in the ingredient list produces a different product to the consumer, so an evaluation that compares before and after under identical conditions is needed.

In planning order, sensory ingredients are often settled later than efficacy actives. In product groups like these launches, where sensory materials also bear on process and wear, it is better to bring that decision forward. In sun care, whether the finish goes matte or luminous affects the film alongside the choice of filter system.

One addition: a material like a gellant is an option that can change the physical form of the product itself. The same ingredient set can be built as a stick or a balm rather than a lotion, and that changes container, usage, portability and even shipping conditions for export. It is worth opening that option once before fixing the format.

• Whether bio-based and biodegradability data were received with raw-material and finished-product levels distinguished
• Whether a plan exists to compare before and after a sensory ingredient swap under identical conditions
• Whether the finish (matte or luminous) in sun care and colour was decided together with the filter system
• Whether changing the format with a gellant was considered as an option

5. One new raw material raises the floor on volume

Decide to use an ingredient seen at a trade show and what binds first is not the formula but volume and documentation. A new raw material carries the supplier's minimum purchase unit, an imported one has its own delivery schedule, and specification sheets, safety data, ingredient information and allergen information have to be secured before the formula can be fixed. Samples arrive quickly; material for production often does not.

For a brand starting small this is where the real floor forms. Even if the formula needs only a little, the material has to be bought in the supplier's unit, so using several new raw materials at once leaves stock that cannot be consumed. COSLAB consults on projects from 1,000 units upward, and what is actually feasible depends on the formula, container, raw materials, process and specification. The practically effective method here is simple: narrow the items using new raw materials to one within the line, and build the rest on materials already in use.

A system material such as a finished dispersion complicates that calculation once more. Several substances arrive bound together, so the unit price looks higher than individual raw materials, while the saving in dispersion work and number of trials sits on the other side. Comparing on raw-material price alone gives no answer; it has to be compared as total first-run cost including process time and repeat testing.

Write the schedule in two layers as well. One is the period for samples and stability testing, the other the period for production material to arrive. If those two do not overlap, production waits even after the formula is fixed. For items using new raw materials it is safer to write both periods down separately and work the launch date back from their sum.

Finally, it helps to prepare one alternative. Supply schedules for new raw materials can move, as can their eligibility in a given market. If the brief holds a second option that keeps the same concept without that ingredient, the schedule can be held; without one, the launch is tied to the supplier's calendar.

• Whether items using new raw materials were narrowed to one within the line
• Whether specification sheets, safety data and allergen information were secured
• Whether the comparison was made on total first-run cost including process time and repeat testing, not raw-material price
• Whether sample and testing periods and production delivery periods were written separately and the launch date worked back from them
• Whether a second option exists that keeps the concept without that ingredient

The first question for the brief

If you are making sun care, try turning the line that read "SPF 50+ PA++++" into two. The first is the target protection figure; the second is how that figure will be built. Whether filters are combined individually or taken as a system the supplier has already dispersed, and whether the process runs hot or cold. The launches at this show have widened the options on that second line, and the choice pulls stability testing scope, container specification and the first-run schedule along with it.

The second thing to write is target markets and the source of the documentation. Record, item by item, whether the intended filter set and new raw materials can be used in every market you plan to sell in, and who confirmed that from which primary source. Supplier material is grounds for selecting an ingredient; grounds for what the product may claim have to be produced on the product. Writing down from the start that raw-material clinical figures will not be moved into product copy avoids rewriting all your claims later.

The last is volume and schedule. Write as numbers how many items will use new raw materials, what the minimum purchase unit and delivery period for each are, and whether those overlap the stability testing period. Each additional new raw material raises the real floor on the first run. The most useful single line to add to the brief right now is how many raw materials are new in this product, and which of them could be removed.